Cromolyn (Na)
Overview
Cromolyn was synthesized in 1965, as part of an attempt to produce an improved bronchodilator copound. Although cromolyn does not have bronchodilator activity, it was found to inhibit antigen-induced bronchospasm. Currently, its major use is as a prophylactic agent in the treatment of mild to moderate asthma. Cromolyn (Na) is also used as a nasal inhaler to treat seasonal allergic rhinitis, as an ophthalmic solution to treat allergic or vernal conjunctivitis. Cromolyn sodium was approved by the FDA in 1973 and went off patent in May 1993.
Categories
- 21 Ophthalmological preparations
- 25 Drugs acting on the respiratory tract
- 25.1 Anti-asthmatic drugs
- 25 Drugs acting on the respiratory tract
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Cromolyn (Na)'s dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 1 to 2 drops | 1.5 (1.5) | 4.8 hourly | Opthalmic | |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Cromolyn (Na) is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Cromolyn (Na) is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Cromolyn (Na)
Back to top
Previous Drug Generic - Next Drug Generic